242 related articles for article (PubMed ID: 23648828)
1. Taxane benefit in breast cancer--a role for grade and chromosomal stability.
A'Hern RP; Jamal-Hanjani M; Szász AM; Johnston SR; Reis-Filho JS; Roylance R; Swanton C
Nat Rev Clin Oncol; 2013 Jun; 10(6):357-64. PubMed ID: 23648828
[TBL] [Abstract][Full Text] [Related]
2. Taxane-based combinations as adjuvant chemotherapy for node-positive ER-positive breast cancer based on 2004-2009 data from the Breast Cancer Registry of the Japanese Breast Cancer Society.
Hojo T; Masuda N; Iwamoto T; Niikura N; Anan K; Aogi K; Ohnishi T; Yamauchi C; Yoshida M; Kinoshita T; Masuoka H; Sagara Y; Sakatani T; Kojima Y; Tsuda H; Kumamaru H; Miyata H; Nakamura S
Breast Cancer; 2020 Jan; 27(1):85-91. PubMed ID: 31327134
[TBL] [Abstract][Full Text] [Related]
3. Colored body images reveal the perceived intensity and distribution of pain in women with breast cancer treated with adjuvant taxanes: a prospective multi-method study of pain experiences.
Hellerstedt-Börjesson S; Nordin K; Fjällskog ML; Rissanen R; Peterson M; Arving C
Scand J Pain; 2018 Oct; 18(4):581-591. PubMed ID: 29949517
[TBL] [Abstract][Full Text] [Related]
4. TLE3 is not a predictive biomarker for taxane sensitivity in the NCIC CTG MA.21 clinical trial.
Bartlett JM; Nielsen TO; Gao D; Gelmon KA; Quintayo MA; Starczynski J; Han L; Burnell MJ; Levine MN; Chen BE; Shepherd LE; Chapman JW;
Br J Cancer; 2015 Sep; 113(5):722-8. PubMed ID: 26284338
[TBL] [Abstract][Full Text] [Related]
5. Loss of p27
Kim GJ; Kim DH; Min KW; Kim YH; Oh YH
Pathol Res Pract; 2018 Apr; 214(4):565-571. PubMed ID: 29482985
[TBL] [Abstract][Full Text] [Related]
6. Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer.
Modi S; DiGiovanna MP; Lu Z; Moskowitz C; Panageas KS; Van Poznak C; Hudis CA; Norton L; Tan L; Stern DF; Carter D; Seidman AD
Cancer Invest; 2005; 23(6):483-7. PubMed ID: 16203655
[TBL] [Abstract][Full Text] [Related]
7. [Chemotherapy for breast cancer refractory to anthracycline, taxane or trastuzumab].
Ito Y; Kobayashi K
Gan To Kagaku Ryoho; 2009 May; 36(5):726-9. PubMed ID: 19461171
[TBL] [Abstract][Full Text] [Related]
8. Taxane-containing regimens for metastatic breast cancer.
Ghersi D; Willson ML; Chan MM; Simes J; Donoghue E; Wilcken N
Cochrane Database Syst Rev; 2015 Jun; 2015(6):CD003366. PubMed ID: 26058962
[TBL] [Abstract][Full Text] [Related]
9. Targeting chromosomal instability and tumour heterogeneity in HER2-positive breast cancer.
Burrell RA; Juul N; Johnston SR; Reis-Filho JS; Szallasi Z; Swanton C
J Cell Biochem; 2010 Nov; 111(4):782-90. PubMed ID: 20665662
[TBL] [Abstract][Full Text] [Related]
10. Optimizing taxane use in MBC in the emerging era of targeted chemotherapy.
von Minckwitz G; Martin M; Wilson G; Alba E; Schmidt M; Biganzoli L; Awada A
Crit Rev Oncol Hematol; 2013 Mar; 85(3):315-31. PubMed ID: 23116625
[TBL] [Abstract][Full Text] [Related]
11. p53 expression in pretreatment specimen predicts response to neoadjuvant chemotherapy including anthracycline and taxane in patients with primary breast cancer.
Shien T; Kinoshita T; Seki K; Yoshida M; Hojo T; Shimizu C; Taira N; Doihara H; Akashi-Tanaka S; Tsuda H; Fujiwara Y
Acta Med Okayama; 2013; 67(3):165-70. PubMed ID: 23804139
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia and Noncoding RNAs in Taxane Resistance.
Pucci P; Rescigno P; Sumanasuriya S; de Bono J; Crea F
Trends Pharmacol Sci; 2018 Aug; 39(8):695-709. PubMed ID: 29891252
[TBL] [Abstract][Full Text] [Related]
13. Specific kinesin expression profiles associated with taxane resistance in basal-like breast cancer.
Tan MH; De S; Bebek G; Orloff MS; Wesolowski R; Downs-Kelly E; Budd GT; Stark GR; Eng C
Breast Cancer Res Treat; 2012 Feb; 131(3):849-58. PubMed ID: 21479552
[TBL] [Abstract][Full Text] [Related]
14. Effects of adding taxane to anthracycline-based neoadjuvant chemotherapy in locally advanced breast cancer.
Rašić A; Sofić A; Bešlija S; Rašić I; Hasanbegović B
Med Glas (Zenica); 2019 Feb; 16(1):77-82. PubMed ID: 30256061
[TBL] [Abstract][Full Text] [Related]
15. GM1 for taxane-induced neuropathy in breast cancer.
Das M
Lancet Oncol; 2019 Jul; 20(7):e348. PubMed ID: 31130320
[No Abstract] [Full Text] [Related]
16. Predictive and Prognostic Value of the TauProtein in Breast Cancer.
Bonneau C; Gurard-Levin ZA; Andre F; Pusztai L; Rouzier R
Anticancer Res; 2015 Oct; 35(10):5179-84. PubMed ID: 26408675
[TBL] [Abstract][Full Text] [Related]
17. Quantitative and clinical description of postural instability in women with breast cancer treated with taxane chemotherapy.
Wampler MA; Topp KS; Miaskowski C; Byl NN; Rugo HS; Hamel K
Arch Phys Med Rehabil; 2007 Aug; 88(8):1002-8. PubMed ID: 17678662
[TBL] [Abstract][Full Text] [Related]
18. Evidence-based use of neoadjuvant taxane in operable and inoperable breast cancer.
Estévez LG; Gradishar WJ
Clin Cancer Res; 2004 May; 10(10):3249-61. PubMed ID: 15161677
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of first-line bevacizumab combined with taxane therapy in Chinese patients with HER2-negative locally recurrent or metastatic breast cancer: findings from the ATHENA study.
Xu BH; Jiang ZF; Shen ZZ; Guan ZZ; Chen ZD; Cheng Y; Zheng H; Jiang J; Wang XJ; Tong ZS; Qin SK; Luo Y; Yao M; Wang LW; He J
Chin Med J (Engl); 2012 Mar; 125(5):764-9. PubMed ID: 22490570
[TBL] [Abstract][Full Text] [Related]
20. Chromosomal instability determines taxane response.
Swanton C; Nicke B; Schuett M; Eklund AC; Ng C; Li Q; Hardcastle T; Lee A; Roy R; East P; Kschischo M; Endesfelder D; Wylie P; Kim SN; Chen JG; Howell M; Ried T; Habermann JK; Auer G; Brenton JD; Szallasi Z; Downward J
Proc Natl Acad Sci U S A; 2009 May; 106(21):8671-6. PubMed ID: 19458043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
